IP Library Granted Patent US 10,195,198
Granted Patent B2
US 10,195,198 · App. 15/323,619 · Granted Feb 5, 2019

Methods and compositions for treating diseases and conditions

Inventors: Anthony P. Ford (Palo Alto, CA); Julian Paton (Bristol, GB)
Assignee: Afferent Pharmaceuticals, Inc.
A61K31/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,198
App. No.
15/323,619
Granted
Feb 5, 2019
Kind
B2
Abstract

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.

Claims (15)

1. A method of treating hypertension in a subject, comprising identifying a subject diagnosed with hypertension and administering to the subject a compound of formula (I):

or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof; wherein:

R 1 is hydrogen or optionally substituted C 1 -C 6 alkyl; and

R 2 is C 1 -C 6 alkyl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; amino; aminosulfonyl; halo; amido; C 1 -C 6 haloalkyl; C 1 -C 6 alkoxy; C 1 -C 6 hydroxy; C 1 -C 6 haloalkoxy; nitro; C 1 -C 6 hydroxyalkyl; C 1 -C 6 alkoxyalkyl; C 1 -C 6 hydroxyalkoxy; C 2 -C 6 alkynylalkoxy; C 1 -C 6 alkylsulfonyl; C 1 -C 6 carboxyalkyl; cyano or C 1 -C 6 alkylcarbonyl.

2. The method of claim 1 wherein said subject diagnosed with hypertension has a systolic blood pressure above 120 mmHg and/or a diastolic pressure above about 80 mmHg.

3. The method of claim 1 , wherein the subject diagnosed with hypertension is diagnosed with chronic treatment resistant hypertension.

4. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 2 , wherein the subject diagnosed with hypertension is diagnosed with chronic treatment resistant hypertension.

6. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound is of the following structure:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is of the following structure:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 17197705 PREVIOUSLY RECORDED AT REEL: 061574 FRAME: 0579. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Dec 1, 2022
From: AFFERENT PHARMACEUTICALS, INC.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 062036/0001 →
CHANGE OF ADDRESS Recorded Sep 30, 2022
From: AFFERENT PHARMACEUTICALS, INC.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 061574/0579 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2018
From: FORD, ANTHONY P; PATON, JULIAN
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 044828/0699 →
Continuity (3)
Provisional Application 62120643 · Feb 25, 2015
Provisional Application 62020839 · Jul 3, 2014
Related Publication 20170151241A1 · Jun 1, 2017